Key result
A systematic review of 9 new small-molecule tyrosine kinase inhibitors targeting VEGFR found similar toxicity profiles and identified potential efficacy and predictive biomarkers awaiting validation.
Systematic Review
While exposure biomarkers for novel VEGF inhibitors have informed clinical trial dosing, predictive and efficacy biomarkers still require validation.
Answers are grounded in this paper and cite their sources.
May support uniform safety monitoring for new VEGFR TKIs; leaves open prospective validation of predictive biomarkers.
BACKGROUND: The development of vascular endothelial growth factor (VEGF) inhibitors of tumour angiogenesis can only be described as prolific. It is therefore interesting to speculate which will reach the clinic. Of course, the most effective agents will succeed, but how is effectiveness measured? When presented with a summary of competitive compounds, it can be difficult to discriminate between their potency on target, toxicity and response rates. OBJECTIVES: A comparison was undertaken between new small-molecule tyrosine kinase inhibitors with vascular endothelial growth factor receptor as one of their targets. Factors considered included mode of action (targets), toxicity and usefulness of biomarker data. METHODOLOGY: We carried out a systematic review using PubMed, MEDLINE and American Society of Clinical Oncologist (ASCO) databases for articles (including abstracts) presented in 2007 - 2009. Search terms included 'angiogenesis inhibitors', 'tyrosine kinase inhibitors', 'VEGF' and 'biomarkers'. Nine compounds were selected for detailed comparison. RESULTS AND CONCLUSIONS: The toxicity profiles of the compounds were similar. Many exposure biomarkers have been identified that have informed the dose and scheduling of these compounds in clinical trials. Progress has also been made in identifying potential efficacy and predictive biomarkers for these new agents; however, these are yet to be validated.
No takes yet. Share an insight, caveat, or question.
Wood et al. (2009) conducted a systematic review in Tumour angiogenesis. Small-molecule tyrosine kinase inhibitors targeting VEGFR was evaluated on Mode of action, toxicity, and usefulness of biomarker data. A systematic review of 9 new small-molecule tyrosine kinase inhibitors targeting VEGFR found similar toxicity profiles and identified potential efficacy and predictive biomarkers awaiting validation.
Synapse has enriched 10 related papers. Consider them for comparative context: